𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab

✍ Scribed by Patricia Formento; Jean-Michel Hannoun-Levi; Jean-Louis Fischel; Nicolas Magné; Marie-Christine Etienne-Grimaldi; Gérard Milano


Book ID
116428323
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
411 KB
Volume
40
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Phase 1/2 dose-escalation study of a GM-
✍ Celestia S. Higano; John M. Corman; David C. Smith; Arthur S. Centeno; Christoph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract ## BACKGROUND This open‐label, multicenter, dose‐escalation study evaluated multiple dose levels of immunotherapy in patients with metastatic hormone‐refractory prostate cancer (HRPC). The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate‐carcinoma cell line